Unbiased avidity-based isolation of antigen-specific T cells

Authors:

Abstract
Background: Cancer immunotherapies have significantly improved treatment efficacy and patient survival by exploiting antigen-specific T cells to eliminate cancer cells. However, current approaches for identifying and isolating antigen-specific T cells typically require prior knowledge of target antigens, limiting discovery, and reducing the ability to consistently detect rare tumor-reactive T cells. We therefore sought to develop an unbiased platform for the identification and enrichment of antigen-specific T cells using naturally processed and presented tumor antigens. Methods: We developed ATTACH (Assessment of T cells Tethered to Antigen Class I Histocompatibility), a microfluidic platform that applies controlled shear stress and leverages tumor cells as a natural source of endogenous major histocompatibility complex (MHC)-peptide complexes to isolate antigen-specific T cells based on MHC/peptide binding avidity. ATTACH was evaluated in both human and mouse systems for its ability to enrich rare tumor-reactive T-cell populations and deplete bystander virus-specific T cells. Results: ATTACH resulted in up to a 10-fold enrichment of antigen-specific T cells across both human and mouse systems, enabling the isolation of clonotypes present at frequencies as low as 0.1%. In addition to enriching rare tumor-reactive T cells, ATTACH efficiently depleted virus-specific bystander T cells. Conclusions: ATTACH provides a streamlined and unbiased approach for the rapid identification and isolation of antigen-specific T cells, and may facilitate the optimization of cellular therapies for the treatment of solid tumors.
Funding Information
  • Exon 20 Group (N/A)
  • Rexanna's Foundation (Bruce Campbell Research Grant)
  • Rexanna's Foundation (The Lance Bertrand Research Grant)
  • American Association for Cancer Research (AACR) Career Development Award in Lung Cancer Research (23-20-01-REUB)
  • Troper Wojcicki Foundation (N/A)
  • Happy Lungs Project (N/A)
  • Department of Defense Lung Cancer Research Program (Idea Development Award / HT9425-23-1-1021)
  • Waun Ki Hong Lung Cancer Research Fund (N/A)
  • Petrin Fund (N/A)
  • LUNGevity Foundation (EGFR Resisters/LUNGevity Foundation EGFR-positive)
  • LUNGevity Foundation (RETpositive/LUNGevity Translational Research Award)
  • Cancer Prevention and Research Institute of Texas (High Impact High Reward Award / RP210137)
  • Cancer Prevention and Research Institute of Texas (Individual Investigator Research Award / RP230363)
  • Cancer Prevention and Research Institute of Texas (Individual Investigator Research Award / RP260357)
  • NCI (SBIR Innovative Concept Award / 75N91025C00012)
  • MD Anderson’s Lung Cancer Moon Shot (N/A)
  • Salgado Family Charitable Fund (N/A)
  • University Cancer Foundation Institutional Research Grant program at the University of Texas MD Anderson Cancer Center (N/A)
  • NIH/NCI (R21 / R21CA283852)

This publication has 57 references indexed in Scilit: